| 3.01 -0.4 (-11.73%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.36 | 1-year : | 13.08 |
| Resists | First : | 8.02 | Second : | 11.19 |
| Pivot price | 3.66 |
|||
| Supports | First : | 2.88 | Second : | 2.39 |
| MAs | MA(5) : | 3.14 |
MA(20) : | 4.08 |
| MA(100) : | 14.33 |
MA(250) : | 48.81 |
|
| MACD | MACD : | -1.3 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 7.8 |
D(3) : | 5.9 |
| RSI | RSI(14): 30.1 |
|||
| 52-week | High : | 138 | Low : | 2.88 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ JUNS ] has closed above bottom band by 27.9%. Bollinger Bands are 60% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.46 - 3.47 | 3.47 - 3.49 |
| Low: | 2.97 - 2.99 | 2.99 - 3 |
| Close: | 2.99 - 3.01 | 3.01 - 3.03 |
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Fri, 28 Aug 2026
Jupiter Neurosciences Received Notice of Delisting - tradingview.com
Fri, 28 Aug 2026
Jupiter Neurosciences (NASDAQ: JUNS) to appeal Nasdaq delisting - Stock Titan
Fri, 21 Aug 2026
Jupiter Neurosciences, Inc. stock plunges 44% after spiking to $11.14 - Cryptonews.net
Fri, 21 Aug 2026
JUNS Stock Whipsaws As New Insider Files Form 3 - StocksToTrade
Fri, 21 Aug 2026
JUNS Stock Jumps As New Insider Stake Hits The Tape - timothysykes.com
Fri, 21 Aug 2026
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -3 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.32e+006 (%) |
| Held by Institutions | 550230 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.82e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -18.71 |
| Profit Margin | 0 % |
| Operating Margin | -11 % |
| Return on Assets (ttm) | 313.4 % |
| Return on Equity (ttm) | -159.6 % |
| Qtrly Rev. Growth | 888.7 % |
| Gross Profit (p.s.) | -0.07 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.17 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 29680 |
| Forward Dividend | 3190 |
| Dividend Yield | 986046% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|